丙型肝炎市场－全球产业规模、份额、趋势、机会及预测（按类型、治疗方法、诊断、给药途径、分销管道、地区和竞争格局划分，2021-2031年）

全球丙型肝炎市场预计将从 2025 年的 93.2 亿美元成长到 2031 年的 131.5 亿美元，年复合成长率为 5.91%。

此业务板块涵盖诊断工具和治疗药物的生产和分销，主要包括用于治疗和根除丙型肝炎病毒感染的直接抗病毒药物（DAA）。市场成长的主要驱动因素是全球疾病负担的加重以及国际上关于病毒根除的指南，这些因素正在推动政府主导的筛检和治疗计画。此外，现代抗病毒疗法的安全性和高成功率提高了患者的依从性，扩大了治疗目标族群，以满足世界卫生组织（WHO）报告的2024年5000万慢性丙型肝炎患者的需求。

儘管有这些积极迹象，但由于先进治疗方法的高昂费用限制了价格敏感型开发中国家的医疗资源获取，市场仍面临许多障碍。低诊断率进一步加剧了这一经济障碍，医疗基础设施不足导致无症状感染者难以被发现。因此，许多感染者未能得到治疗，阻碍了市场充分发挥潜力，并延缓了全球根除疫情的努力。

市场驱动因素

政府主导的疾病消除计画的实施是推动各国推动与全球卫生目标相符策略的关键市场催化剂。此类大规模公共卫生系统需要大量采购诊断试剂和药品，为产业相关人员建立稳健的商业管道。英国在这方面取得了成功，证明了国家主导工作的有效性。根据病毒性肝炎预防委员会于2024年11月发布的《2024年英格兰丙型肝炎报告》中的分析，英国的国家消除策略将丙型肝炎相关死亡率降低至每10万人0.41例，超过了世界卫生组织（世卫组织）的目标，这充分体现了资助干预措施的价值。

在这些政策的配合下，先进的直接抗病毒疗法（DAA）的广泛应用使得确诊患者能够得到快速有效的治疗，从而推动了市场扩张。这些现代治疗方法具有卓越的安全性，且给药方案简化，显着提高了治疗的可近性，并促使全球治疗人数增加。英国肝臟信託基金会于2025年4月发布的《2024年英格兰丙型肝炎报告》强调了这一日益增长的需求，该报告指出，96.1%的确诊患者已开始接受治疗。然而，全球疾病负担仍是推动需求的主要因素。美国疾病管制与预防中心（CDC）于2025年7月发布的《全球病毒性肝炎》最新报告显示，前一年全球约有100万例新增感染病例，凸显了市场对解决方案的持续需求。

市场挑战

先进抗病毒疗法的高昂采集费用严重阻碍因素了市场成长，尤其是在医疗资源有限的开发中国家。这些高定价模式往往超出公共医疗系统和个人患者的承受能力，从而限制了治疗的可及性。这些经济壁垒阻碍了市场利用该地区高发病率的机会，导致在急需医疗干预的地区出现重大商机损失和市场准入受限。

此外，医疗基础设施的匮乏加剧了这项挑战，阻碍了对感染者的识别。诊断能力的不足导致大量患者不了解自身感染状况，也无法获得所需的治疗。世界卫生组织（世卫组织）预测，到2024年，全球仅有36%的C型肝炎感染者能够确诊。如此巨大的诊断缺口有效地缩小了潜在市场规模，直接阻碍了市场的整体扩张，因为大多数潜在的治疗候选人仍未被发现和治疗。

市场趋势

将医疗服务下放至社区药局正在改变服务提供方式，将治疗启动从中心化医院转移到当地社区药局。这一趋势有助于克服基础设施的限制，使药剂师能够筛检和开立直接抗病毒药物，从而有效地接触到那些在传统医疗路径中常常被忽略的患者。美国国立卫生研究院 (NIH) 于 2025 年 10 月发表的一项题为《药剂师参与丙型肝炎管理》的研究表明，这种模式能够有效地弥合从诊断到治疗启动之间的差距。药剂师主导的措施实现了 66.5% 的治疗启动率，显着高于传统的转诊方式。透过简化患者体验，这种方法提高了患者的用药依从性，并扩大了高发生率地区的市场覆盖范围。

同时，数位化检测治疗平台的普及应用正在加速市场渗透，透过虚拟医疗互动解决地域隔离问题。这些整合的远距医疗系统使医疗服务提供者能够远距诊断病情并开立处方，从而免去了服务不足地区患者前往实体诊所就诊的需要。奥勒冈健康与科学大学2024年11月发布的一份题为《远端医疗结合社区同侪支持可提高农村地区丙型肝炎患者的治疗成功率》的报告，清晰地展现了其对难以触及人群的影响。报告显示，接受远端医疗服务的患者中有85%成功註册治疗，而对照组的比例仅为12%。如此高的接受率表明，数位化平台对于刺激医疗设施匮乏地区的需求至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球C型肝炎市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（急性C型肝炎、慢性C型肝炎、其他）
  • 治疗方法（抗病毒药物、疫苗、免疫调节药物、手术、其他）
  • 透过诊断（切片检查、血液检查、影像检查、其他）
  • 依给药途径（口服、注射、其他）
  • 通路（医院药房、零售药房、网路药房、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美C型肝炎市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲丙型肝炎市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区丙型肝炎市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲C型肝炎市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美丙型肝炎市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球C型肝炎市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• GlaxoSmithKline plc
• Novartis AG
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Bayer AG
• Merck & Co., Inc.
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company B

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hepatitis C Market is projected to expand from USD 9.32 Billion in 2025 to USD 13.15 Billion by 2031, reflecting a compound annual growth rate of 5.91%. This sector encompasses the manufacturing and distribution of diagnostic tools and therapeutic agents, specifically Direct Acting Antivirals utilized to manage and eradicate hepatitis C infections. The market's upward trajectory is primarily fueled by the rising global disease burden and international directives for viral elimination, which promote government-sponsored screening and treatment programs. Furthermore, the safety and high success rates of modern antiviral regimens enhance patient compliance and broaden the treatable demographic, addressing the needs of the 50 million individuals reported by the World Health Organization in 2024 to be living with chronic hepatitis C.

Despite these positive indicators, the market encounters substantial obstacles due to the prohibitive costs of advanced therapies, which limit availability in developing nations with high price sensitivity. This financial hurdle is compounded by low rates of diagnosis, as inadequate healthcare infrastructure in these areas fails to identify asymptomatic carriers. Consequently, a significant number of infected individuals remain without treatment, a situation that prevents the market from reaching its full potential and decelerates global elimination initiatives.

Market Driver

The execution of Government-Led Disease Elimination Programs acts as a crucial market catalyst, with nations implementing strategies to align with international health objectives. These extensive public health structures require significant procurement of diagnostics and medications, establishing a reliable commercial channel for industry participants. The United Kingdom exemplifies success in this area, proving the effectiveness of state-managed efforts; the Viral Hepatitis Prevention Board's November 2024 analysis in the 'HCV in England report 2024' indicates that the national elimination strategy reduced hepatitis C-related mortality to 0.41 per 100,000 people, exceeding World Health Organization targets and demonstrating the value of funded interventions.

Complementing these policies, the broad uptake of Advanced Direct-Acting Antiviral Therapies propels market expansion by facilitating rapid and effective cures for diagnosed patients. The superior safety profile and simplified dosing schedules of these modern treatments have markedly enhanced linkage-to-care statistics, resulting in increased treatment volumes worldwide. This demand is highlighted by the British Liver Trust's April 2025 'Hepatitis C in England 2024' report, which noted that 96.1% of diagnosed individuals connected to care began treatment. Nevertheless, the global disease burden remains a primary driver of demand; the Centers for Disease Control and Prevention reported in their July 2025 'Global Viral Hepatitis' update that approximately 1 million new infections occurred globally in the previous year, emphasizing the persistent need for market solutions.

Market Challenge

The substantial acquisition costs associated with advanced antiviral therapies act as a major constraint on market growth, especially within developing economies where healthcare resources are scarce. These elevated pricing models often surpass the financial limits of public health systems and individual patients, thereby restricting the quantity of treatments distributed. Such economic barriers hinder the market's ability to leverage the high disease prevalence in these regions, leading to significant revenue forfeiture and restricted market entry in areas that otherwise demonstrate a strong need for medical intervention.

Additionally, the absence of robust healthcare infrastructure aggravates this challenge by impeding the identification of the infected population. Insufficient diagnostic capabilities mean that a vast number of patients remain unaware of their condition, preventing them from accessing essential therapies. According to the World Health Organization, only 36% of individuals living with hepatitis C worldwide were diagnosed in 2024. This substantial diagnosis gap effectively diminishes the size of the addressable market, as the majority of potential candidates for therapeutic agents remain undetected and untreated, which directly stalls overall market expansion.

Market Trends

The Decentralization of Care to Community Pharmacies is reshaping service delivery by moving treatment initiation from centralized hospitals to readily accessible local drugstores. This trend helps overcome infrastructure limitations by enabling pharmacists to administer screenings and prescribe direct-acting antivirals, effectively engaging patients who might otherwise be lost in traditional care pathways. The National Institutes of Health's October 2025 study, 'Pharmacist Involvement in Hepatitis C Management,' validates the efficacy of this model in bridging the gap between diagnosis and cure, revealing that pharmacist-led initiatives achieved a therapy initiation rate of 66.5%, which is significantly higher than standard referral methods. By streamlining the patient experience, this approach improves adherence and broadens the market reach within high-prevalence communities.

Concurrently, the Adoption of Digital Test-to-Treat Platforms is increasing market penetration by resolving issues of geographical isolation through virtual healthcare interactions. These integrated telemedicine systems enable providers to diagnose conditions and prescribe curative treatments remotely, eliminating the need for physical clinic visits in underserved areas. The impact on engaging hard-to-reach populations is evident in Oregon Health & Science University's November 2024 report, 'Telehealth plus local peer support boosts treatment success for hepatitis C in rural patients,' which found that 85% of patients referred to telehealth services successfully enrolled in treatment compared to just 12% in the control group. This high uptake demonstrates that digital platforms are essential for stimulating demand in regions lacking adequate medical facilities.

Key Market Players

• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Bayer AG
• Merck & Co., Inc.
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company B

Report Scope

In this report, the Global Hepatitis C Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis C Market, By Type

• Acute Hepatitis C
• Chronic Hepatitis C
• Others

Hepatitis C Market, By Treatment

• Antiviral Drugs
• Vaccine
• Immune Modulator Drugs
• Surgery
• Others

Hepatitis C Market, By Diagnosis

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Others

Hepatitis C Market, By Route of Administration

• Oral
• Parenteral
• Others

Hepatitis C Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hepatitis C Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis C Market.

Available Customizations:

Global Hepatitis C Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatitis C Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Acute Hepatitis C, Chronic Hepatitis C, Others)
  • 5.2.2. By Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others)
  • 5.2.3. By Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others)
  • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Hepatitis C Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By Route of Administration
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hepatitis C Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Diagnosis
      • 6.3.1.2.4. By Route of Administration
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Hepatitis C Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Diagnosis
      • 6.3.2.2.4. By Route of Administration
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Hepatitis C Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Diagnosis
      • 6.3.3.2.4. By Route of Administration
      • 6.3.3.2.5. By Distribution Channel

7. Europe Hepatitis C Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By Route of Administration
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hepatitis C Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Diagnosis
      • 7.3.1.2.4. By Route of Administration
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Hepatitis C Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Diagnosis
      • 7.3.2.2.4. By Route of Administration
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Hepatitis C Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Diagnosis
      • 7.3.3.2.4. By Route of Administration
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Hepatitis C Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Diagnosis
      • 7.3.4.2.4. By Route of Administration
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Hepatitis C Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Diagnosis
      • 7.3.5.2.4. By Route of Administration
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Hepatitis C Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By Route of Administration
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hepatitis C Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Diagnosis
      • 8.3.1.2.4. By Route of Administration
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Hepatitis C Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Diagnosis
      • 8.3.2.2.4. By Route of Administration
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Hepatitis C Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Diagnosis
      • 8.3.3.2.4. By Route of Administration
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Hepatitis C Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Diagnosis
      • 8.3.4.2.4. By Route of Administration
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Hepatitis C Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Diagnosis
      • 8.3.5.2.4. By Route of Administration
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Hepatitis C Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By Route of Administration
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hepatitis C Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Diagnosis
      • 9.3.1.2.4. By Route of Administration
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Hepatitis C Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Diagnosis
      • 9.3.2.2.4. By Route of Administration
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Hepatitis C Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Diagnosis
      • 9.3.3.2.4. By Route of Administration
      • 9.3.3.2.5. By Distribution Channel

10. South America Hepatitis C Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Diagnosis
  • 10.2.4. By Route of Administration
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hepatitis C Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Diagnosis
      • 10.3.1.2.4. By Route of Administration
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Hepatitis C Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Diagnosis
      • 10.3.2.2.4. By Route of Administration
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Hepatitis C Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Diagnosis
      • 10.3.3.2.4. By Route of Administration
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hepatitis C Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GlaxoSmithKline plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Mylan N.V.
• 15.4. Teva Pharmaceutical Industries Ltd.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Bayer AG
• 15.7. Merck & Co., Inc.
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Bristol-Myers Squibb Company B

16. Strategic Recommendations

17. About Us & Disclaimer